Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration
© 2022 by The American Society of Hematology..
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are based on a range of novel platforms, with adenovirus-based approaches (like ChAdOx1 nCov-19) being one of them. Recently, a novel complication of SARS-CoV-2-targeted adenovirus vaccines has emerged: immune thrombocytopenia, either isolated, or accompanied by thrombosis (then termed VITT). This complication is characterized by low platelet counts, and in the case of VITT, also by platelet-activating platelet factor 4 antibodies reminiscent of heparin-induced thrombocytopenia, leading to a prothrombotic state with clot formation at unusual anatomic sites. Here, we detected antiplatelet antibodies targeting platelet glycoprotein receptors in 30% of patients with proven VITT (n = 27) and 42% of patients with isolated thrombocytopenia after ChAdOx1 nCov-19 vaccination (n = 26), indicating broad antiplatelet autoimmunity in these clinical entities. We use in vitro and in vivo models to characterize possible mechanisms of these platelet-targeted autoimmune responses leading to thrombocytopenia. We show that IV but not intramuscular injection of ChAdOx1 nCov-19 triggers platelet-adenovirus aggregate formation and platelet activation in mice. After IV injection, these aggregates are phagocytosed by macrophages in the spleen, and platelet remnants are found in the marginal zone and follicles. This is followed by a pronounced B-cell response with the emergence of circulating antibodies binding to platelets. Our work contributes to the understanding of platelet-associated complications after ChAdOx1 nCov-19 administration and highlights accidental IV injection as a potential mechanism of platelet-targeted autoimmunity. Hence, preventing IV injection when administering adenovirus-based vaccines could be a potential measure against platelet-associated pathologies after vaccination.
| Errataetall: |
CommentIn: Blood. 2022 Aug 4;140(5):413-414. - PMID 35925641 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:140 |
|---|---|
| Enthalten in: |
Blood - 140(2022), 5 vom: 04. Aug., Seite 478-490 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nicolai, Leo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
37270-94-3 |
|---|
| Anmerkungen: |
Date Completed 08.08.2022 Date Revised 13.09.2022 published: Print CommentIn: Blood. 2022 Aug 4;140(5):413-414. - PMID 35925641 Citation Status MEDLINE |
|---|
| doi: |
10.1182/blood.2021014712 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340156651 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340156651 | ||
| 003 | DE-627 | ||
| 005 | 20231226004515.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2021014712 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1133.xml |
| 035 | |a (DE-627)NLM340156651 | ||
| 035 | |a (NLM)35486845 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nicolai, Leo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.08.2022 | ||
| 500 | |a Date Revised 13.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Blood. 2022 Aug 4;140(5):413-414. - PMID 35925641 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 by The American Society of Hematology. | ||
| 520 | |a Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are based on a range of novel platforms, with adenovirus-based approaches (like ChAdOx1 nCov-19) being one of them. Recently, a novel complication of SARS-CoV-2-targeted adenovirus vaccines has emerged: immune thrombocytopenia, either isolated, or accompanied by thrombosis (then termed VITT). This complication is characterized by low platelet counts, and in the case of VITT, also by platelet-activating platelet factor 4 antibodies reminiscent of heparin-induced thrombocytopenia, leading to a prothrombotic state with clot formation at unusual anatomic sites. Here, we detected antiplatelet antibodies targeting platelet glycoprotein receptors in 30% of patients with proven VITT (n = 27) and 42% of patients with isolated thrombocytopenia after ChAdOx1 nCov-19 vaccination (n = 26), indicating broad antiplatelet autoimmunity in these clinical entities. We use in vitro and in vivo models to characterize possible mechanisms of these platelet-targeted autoimmune responses leading to thrombocytopenia. We show that IV but not intramuscular injection of ChAdOx1 nCov-19 triggers platelet-adenovirus aggregate formation and platelet activation in mice. After IV injection, these aggregates are phagocytosed by macrophages in the spleen, and platelet remnants are found in the marginal zone and follicles. This is followed by a pronounced B-cell response with the emergence of circulating antibodies binding to platelets. Our work contributes to the understanding of platelet-associated complications after ChAdOx1 nCov-19 administration and highlights accidental IV injection as a potential mechanism of platelet-targeted autoimmunity. Hence, preventing IV injection when administering adenovirus-based vaccines could be a potential measure against platelet-associated pathologies after vaccination | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Platelet Factor 4 |2 NLM | |
| 650 | 7 | |a 37270-94-3 |2 NLM | |
| 650 | 7 | |a ChAdOx1 nCoV-19 |2 NLM | |
| 650 | 7 | |a B5S3K2V0G8 |2 NLM | |
| 700 | 1 | |a Leunig, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Pekayvaz, Kami |e verfasserin |4 aut | |
| 700 | 1 | |a Esefeld, Max |e verfasserin |4 aut | |
| 700 | 1 | |a Anjum, Afra |e verfasserin |4 aut | |
| 700 | 1 | |a Rath, Justina |e verfasserin |4 aut | |
| 700 | 1 | |a Riedlinger, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Ehreiser, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Mader, Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Eivers, Luke |e verfasserin |4 aut | |
| 700 | 1 | |a Hoffknecht, Marie-Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Zhe |e verfasserin |4 aut | |
| 700 | 1 | |a Kugelmann, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Rossaro, Dario |e verfasserin |4 aut | |
| 700 | 1 | |a Escaig, Raphael |e verfasserin |4 aut | |
| 700 | 1 | |a Kaiser, Rainer |e verfasserin |4 aut | |
| 700 | 1 | |a Polewka, Vivien |e verfasserin |4 aut | |
| 700 | 1 | |a Titova, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Petzold, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Spiekermann, Karsten |e verfasserin |4 aut | |
| 700 | 1 | |a Iannacone, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Thiele, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Greinacher, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Stark, Konstantin |e verfasserin |4 aut | |
| 700 | 1 | |a Massberg, Steffen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d 1946 |g 140(2022), 5 vom: 04. Aug., Seite 478-490 |w (DE-627)NLM000014761 |x 1528-0020 |7 nnns |
| 773 | 1 | 8 | |g volume:140 |g year:2022 |g number:5 |g day:04 |g month:08 |g pages:478-490 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood.2021014712 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 140 |j 2022 |e 5 |b 04 |c 08 |h 478-490 | ||